BioLeap Forms Research Collaboration with Kyorin

BioLeap will use its proprietary technology in computational fragment-based design to identify compounds aimed at biological targets of interest to Kyorin.

New Jersey-based BioLeap, a developer of molecular design technology, has established a research collaboration with Tokyo-based Kyorin Pharmaceuticals to produce novel drug candidates.

BioLeap will use its proprietary technology in computational fragment-based design to identify compounds aimed at biological targets of interest to Kyorin. A team from both companies will then select compounds for synthesis and in vitro and in vivo evaluation by Kyorin.

BioLeap uses its proprietary software to design drug candidates through its internal programmes and in collaboration with partners. In the first six months of 2011, the firm entered into research agreements with DuPont, Syngenta, and Unilever.